Tarsus Pharmaceuticals Plunges 12.52% as BlackRock, Boothbay Trim Stakes

On May 2, 2025, Tarsus experienced a significant drop of 12.52% in pre-market trading, sparking concerns among investors about the company's recent developments.

BlackRock, Inc. recently reduced its stake in Tarsus Pharmaceuticals, selling 446,110 shares at $51.37 per share. This move leaves BlackRock with 3,092,735 shares, indicating a potential shift in the firm's investment strategy regarding Tarsus.

Boothbay Fund Management LLC also trimmed its stake in Tarsus, although specific details on the number of shares sold were not disclosed. This reduction in holdings by a major investor could signal a lack of confidence in the company's near-term prospects.